Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Zenas BioPharma, Inc. securities related to its September 2024 IPO, alleging misleading statements in the Registration Statement [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Zenas BioPharma overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to materially false public statements [5]. - Investors who purchased Zenas BioPharma securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by June 16, 2025, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions for investors [4].
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO